Mary Reumuth
Finanzdirektor/CFO bei KALA BIO, INC.
Vermögen: 462 797 $ am 30.04.2024
Aktive Positionen von Mary Reumuth
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
KALA BIO, INC. | Comptroller/Controller/Auditor | 01.02.2014 | - |
Finanzdirektor/CFO | 01.02.2014 | - | |
Treasurer | 01.02.2014 | 01.07.2017 | |
OLINK HOLDING AB | Direktor/Vorstandsmitglied | 07.04.2022 | - |
Independent Dir/Board Member | 07.04.2022 | - |
Karriereverlauf von Mary Reumuth
Ehemalige bekannte Positionen von Mary Reumuth
Unternehmen | Position | Beginn | Ende |
---|---|---|---|
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Comptroller/Controller/Auditor | 01.05.2011 | 01.06.2012 |
VERENIUM CORP | Finanzdirektor/CFO | 01.12.2007 | 01.03.2011 |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Corporate Officer/Principal | - | - |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
Ausbildung von Mary Reumuth
Texas A&M University | Undergraduate Degree |
Statistik
International
Vereinigte Staaten | 6 |
Kanada | 2 |
Schweden | 2 |
Operativ
Comptroller/Controller/Auditor | 2 |
Director of Finance/CFO | 2 |
Corporate Officer/Principal | 2 |
Sektoral
Health Technology | 6 |
Commercial Services | 2 |
Consumer Services | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
KALA BIO, INC. | Health Technology |
OLINK HOLDING AB | Health Technology |
Private Unternehmen | 4 |
---|---|
Enobia Pharma, Inc.
Enobia Pharma, Inc. Pharmaceuticals: MajorHealth Technology Enobia Pharma, Inc. develops therapies to treat patients with ultra-rare and life-threatening genetic metabolic bone disorders. Its lead product candidate, asfotase alfa or ENB-0040, is a treatment for hypophosphatasia—a life-threatening disease that can cause skeletal deformity, severe muscle weakness and progressive damage to vital organs. The company was founded in 1997 and is headquartered in Montreal, Canada. | Health Technology |
Genzyme Corp.
Genzyme Corp. Medical SpecialtiesHealth Technology Genzyme Corp. engages in development and manufacture of specialty therapeutic, surgical and diagnostic product. It serves in the areas of rare genetic diseases, multiple sclerosis, cardiovascular diseases and endocrinology. The company was founded on June 8, 1981 and is headquartered in Cambridge, MA. | Health Technology |
Ernst & Young LLP
Ernst & Young LLP Miscellaneous Commercial ServicesCommercial Services Ernst & Young LLP engages in the provision of accounting, assurance, tax, transaction, and advisory services. It specializes in the actuarial, analytics and big data, cyber security, accounting compliance and reporting, center for board matters, international financial reporting standards, country tax advisory, global trade, tax accounting, and climate change and sustainability. The company was founded in 1989 and is headquartered in New York, NY. | Commercial Services |
Verenium Corp.
Verenium Corp. BiotechnologyHealth Technology Verenium Corp. produces cellulosic ethanol derived from multiple biomass feedstocks. It manufactures and markets enzyme products in the fields of animal health and nutrition, grain processing, oilseed processing, oilfield services and other industrial processes such as pulp and paper and textiles. The company was founded in December 1992 and is headquartered in San Diego, CA. | Health Technology |
- Börse
- Insiders
- Mary Reumuth
- Erfahrung